What is the recommended perioperative pharmacologic approach to pheochromocytoma?

Study for the Disorders of the Adrenal Gland Test. Use flashcards and multiple-choice questions, each with hints and explanations. Prepare for your exam!

Multiple Choice

What is the recommended perioperative pharmacologic approach to pheochromocytoma?

Explanation:
Blocking alpha-adrenergic effects before manipulating the tumor is the cornerstone of management. Catecholamine surges during pheochromocytoma surgery cause dangerous spikes in blood pressure primarily via alpha-1–mediated vasoconstriction, so starting with alpha-blockade blunts these surges and prevents hypertensive crises. After adequate alpha-blockade is established, expanding the intravascular volume helps counter chronic vasoconstriction and reduces the risk of postoperative hypotension once the tumor’s catecholamine input drops. If tachycardia or arrhythmias persist, a beta-blocker can be added, but only after alpha-blockade to avoid unopposed alpha activity that could worsen hypertension. Other approaches, like using ACE inhibitors alone, don’t address the acute vasoconstrictive threat, and avoiding preoperative blockade is dangerous.

Blocking alpha-adrenergic effects before manipulating the tumor is the cornerstone of management. Catecholamine surges during pheochromocytoma surgery cause dangerous spikes in blood pressure primarily via alpha-1–mediated vasoconstriction, so starting with alpha-blockade blunts these surges and prevents hypertensive crises. After adequate alpha-blockade is established, expanding the intravascular volume helps counter chronic vasoconstriction and reduces the risk of postoperative hypotension once the tumor’s catecholamine input drops. If tachycardia or arrhythmias persist, a beta-blocker can be added, but only after alpha-blockade to avoid unopposed alpha activity that could worsen hypertension. Other approaches, like using ACE inhibitors alone, don’t address the acute vasoconstrictive threat, and avoiding preoperative blockade is dangerous.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy